Myeloma Treatment: Abbv-383 BCMA x CD3 Bispecific Antibody Shows Promising Safety and Efficacy in Phase I Study for Relapsed/Refractory Patients 

Dr. Ravi Vij reports on the safety and efficacy of Abbv-383 dosed intravenously, once every three weeks, in patients with relapsed/refractory multiple myeloma. 

Abstract Title:

Breaking Ground in Myeloma Treatment: Abbv-383 BCMA x CD3 Bispecific Antibody Shows Promising Safety and Efficacy in Phase I Study for Relapsed/Refractory Patients Presented at ASH 2023   

What is the purpose of this trial?  

In this study, researchers are exploring a new treatment called Abbv-383 for individuals with relapsed or refractory multiple myeloma (RRMM). Abbv-383 is a special kind of antibody designed to target both myeloma cells and T cells in the immune system. The aim of the study is to understand how safe and effective Abbv-383 is at different dose levels when given intravenously every three weeks. Previous research has shown promising results, and in this report, researchers share information about the safety and how well Abbv-383 works at doses of 20 mg, 40 mg, and 60 mg. 

In this video: 

Ravi Vij, MD, MBA, reports on the safety and efficacy of Abbv-383 dosed intravenously, once every three weeks, in patients with relapsed/refractory multiple myeloma. 

Conclusion: 

Abbv-383 demonstrated a safe profile at doses of 20 mg, 40 mg, and 60 mg given every three weeks, with few side effects leading to discontinuation. The longer dosing interval without a gradual increase in dosage may offer added convenience. However, it's important to note that the 20 mg dose showed slightly lower responses compared to 40 mg and 60 mg. Notably, at 40 mg and 60 mg, Abbv-383 as a standalone treatment led to significant and lasting responses, with a median progression-free survival (mPFS) of 13.7 months and 11.2 months, and a 12-month duration of response (DOR) of 70% and 66% (with DOR not reached in patients with a complete response or better), respectively. 

Trial Information: Abstract #3378 

Doctor Bio: 

Ravi Vij, MD, MBA, individual specializes in the treatment of hematologic malignancies and hematopoietic stem cell transplantation. He holds positions on the Core Transplant, Myeloma, and Leukemia Committees of the CALGB, the Myeloma Committee of the BMT Clinical Trials Network (CTN), and the Multiple Myeloma Cancer Immunotherapy Guideline Panel of the Society for Immunotherapy of Cancer. Additionally, Dr. Vij has contributed to the American Society of Clinical Oncology and the American Society of Hematology Scientific Committees on Plasma Cell Dyscrasias.   

As principal investigator for numerous national and institutional clinical trials, Dr. Vij has focused on improving outcomes for patients with multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes. His involvement has played a crucial role in the development of drugs approved for multiple myeloma. He oversees an active clinical research program in multiple myeloma and leads the Multiple Myeloma Tissue Banking Initiative. 

His initiatives include personalized medicine and immunotherapy studies for the treatment of multiple myeloma, such as research involving CAR-T cells and T cell engagers.